戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              RAMP consists of coexpressing in cultured cells (i) an o
2                                              RAMP interactions have been identified for about 50 GPCR
3                                              RAMP's first stage is carried out above the barrier at t
4                                              RAMPs (1-3) are single transmembrane accessory proteins
5                                              RAMPs (receptor activity modifying proteins) impart rema
6                                              RAMPs are required to transport CRLR to the plasma membr
7  with receptor activity-modifying protein 1 (RAMP 1).
8  both receptor activity-modifying protein-1 (RAMP-1) and calcitonin receptor gene (CT-R) expression i
9 ing body development and EPS production in a RAMP-dependent manner.
10 ally to the cell surface in these cells in a RAMP-independent manner, resulting in both free and RAMP
11                                          All RAMP 1 mutants were able to associate with CRLR with ful
12                                     Although RAMPs have been previously studied in the context of the
13 d specificity, we have co-expressed CRLR and RAMP proteins in the yeast Saccharomyces cerevisiae, whi
14 en other members of this receptor family and RAMP proteins.
15 dependent manner, resulting in both free and RAMP-associated receptor on the cell surface.
16 pied receptors revealed that both ligand and RAMP control mG(s) coupling and defined how agonist enga
17 amily of receptors displays both ligand- and RAMP-dependent signaling bias among the Galphas, Galphai
18 man RAMP-GPCR disease-causing mutations, and RAMP-related human pathologies, paving the way for a new
19                   How the three agonists and RAMPs modulate CLR binding to transducer proteins remain
20 R subunit distributions favored free CTR and RAMPs and that rat amylin promoted association of the co
21 d found expression correlation for GPCRs and RAMPs.
22                                   We applied RAMP to examine how endonucleolytic cleavages of the mou
23                                 We benchmark RAMP against traditional FBA on genome-scale metabolic r
24 ily and identify robust interactions between RAMPs and nearly all chemokine receptors.
25 otif, present as five tandem repeats in both RAMP and DXS6673E.
26 iomarkers, were determined in each sample by RAMP immunoassay.
27 le cAMP inhibition by CXCR4 is unaffected by RAMPs, basal and ligand-stimulated beta-arrestin recruit
28 as the stochastic elements dissipate, and C) RAMP can identify biologically tolerable diversity of a
29 atures of the crRNAs associated with the Cas RAMP module (Cmr) effector complex, which cleaves target
30 e synthesis factor produces a characteristic RAMP profile that exhibits consistency across a range of
31                          These different CLR-RAMP interactions yield discrete receptor pharmacology a
32 rationale for this third agonist for the CLR-RAMP complexes is unclear.
33 G(s)) yielded a mobility-shifted agonist.CLR.RAMP.mG(s) quaternary complex gel band that was sensitiv
34 nist-promoted G protein coupling to each CLR.RAMP complex.
35 t-solubilized fluorescent protein-tagged CLR.RAMP complexes expressed in mammalian cells.
36 nd may inform drug development targeting CLR:RAMP complexes.
37 rgy homeostasis, but the significance of CNS RAMPs in the control of energy balance remains unknown.
38 uman RAMP 1, three mutants were constructed: RAMP 1 without the cytoplasmic tail, a chimera consistin
39 constructions of native type III Cmr (CRISPR RAMP module) complexes in the absence and presence of ta
40 the CRLR-RAMP3 complex and NHERF-1, the CRLR-RAMP complex desensitizes but is unable to internalize u
41 y, we observed that in HEK293 cells the CRLR-RAMP complex undergoes agonist-stimulated desensitizatio
42              The internalization of the CRLR-RAMP complex was not affected by NHERF-1 when CRLR was c
43  agonist-induced internalization of the CRLR-RAMP complex.
44 odifying proteins (RAMPs) showed that a CRLR/RAMP receptor complex is required for intermedin signali
45 rtensive rats via interactions with the CRLR/RAMP receptor complexes.
46 ide family capable of signaling through CRLR/RAMP receptor complexes provides an additional player in
47                                      The CTR/RAMP complexes form three distinct amylin receptors.
48 8p11, to a novel gene at 13q11-12 designated RAMP .
49 ells to characterize the effect of different RAMP and ligand combinations on this pathway.
50                                       During RAMP, nicotine increased the initial SkBF at 42 degrees
51 ells in the presence or absence of exogenous RAMP transfection, although the secretin receptor traffi
52 on approaches, we comprehensively screen for RAMP interactions within the chemokine receptor family a
53 -R and suggest a broader regulatory role for RAMPs in receptor trafficking.
54            To elucidate a comprehensive GPCR-RAMP interactome, we created a library of 215 dual epito
55 fied for about 50 GPCRs, but only a few GPCR-RAMP complexes have been studied in detail.
56 ign of selective therapeutics targeting GPCR-RAMP complexes.
57                             Mapping the GPCR-RAMP interactome expands the current system-wide functio
58                           Screening the GPCR-RAMP pairs with customized multiplexed suspension bead a
59           How peptides selectively bind GPCR:RAMP complexes is unknown.
60                                     Hospital RAMP outlier status is a rectal cancer surgery composite
61       However, it is unknown whether and how RAMP proteins may affect PTH1R function.
62 results reveal unexpected differences in how RAMPs determine CTR and CLR peptide selectivity and supp
63 ncovered novel RAMP-GPCR interactions, human RAMP-GPCR disease-causing mutations, and RAMP-related hu
64 ransmembrane, TM; and tail domains) of human RAMP 1, three mutants were constructed: RAMP 1 without t
65            Resurging interest in identifying RAMP-GPCR interactions has recently been fueled by coevo
66    We show that, in the absence of a ligand, RAMPs do not affect the cell membrane localization or co
67           Although the three known mammalian RAMPs differ in their sequences and tissue expression, r
68 anoparticles in a phase transitional matrix (RAMP) system capable of seamlessly transforming their st
69 this requires the reference standard method (RAMP(R) immunoassay)) or alternatively on the basis of t
70    Heating occurred at one site over 15 min (RAMP) and over 90 s (STEP) at another site, and was main
71                                    Moreover, RAMP has the properties that: A) metabolic states are (L
72 , high outlier (worse than expected), or non-RAMP outlier using standard observed-to-expected methodo
73  variability in model performance, our novel RAMP approach is able to extract more information in ter
74 highlight recent papers that uncovered novel RAMP-GPCR interactions, human RAMP-GPCR disease-causing
75 t in which the N-terminal 641 amino acids of RAMP become joined to the tyrosine kinase domain of FGFR
76 t system-wide functional characterization of RAMP-interacting GPCRs to inform the design of selective
77  The results are discussed in the context of RAMP interactions probed through molecular modeling and
78 rived growth factor receptor, and the ECD of RAMP 1 alone.
79 mic tail, a chimera consisting of the ECD of RAMP 1 and the TM and tail of the platelet-derived growt
80                    In conclusion, the ECD of RAMP 1 is sufficient for normal CRLR association and eff
81 pathologies, paving the way for a new era of RAMP-targeted drug development.
82                       The C-terminal tail of RAMP 1 is unnecessary for CRLR function.
83 ffects on Family B GPCRs, the coevolution of RAMPs with many GPCR families suggests an expanded reper
84 ding the molecular details of the effects of RAMPs on CLR.
85         Here, we characterize the effects of RAMPs on CXCR4 and ACKR3 function.
86               Yet, the functional effects of RAMPs on the CXCL12 signaling axis remain largely elusiv
87                   In contrast, expression of RAMPs 1, 2, and 3 was unaffected by low oxygen tension.
88    Such previously unrecognized functions of RAMPs highlight the need to consider all receptor-intera
89 s study further highlights the importance of RAMPs to CLR pharmacology and to bias in general, as wel
90 f Nt-CRLR to bind CGRP and AM independent of RAMPs was determined by studying inhibition of (125)I-CG
91  of CRLR was not affected by the presence of RAMPs in yeast, indicating that glycosylation of CRLR is
92                       To analyze the role of RAMPs in determining ligand specificity, we have co-expr
93 m of this study was to determine the role of RAMPs in receptor trafficking.
94        These data uncover a critical role of RAMPs in the activation and signaling of a GPCR that may
95 g evidence for interaction with at least one RAMP.
96 lled receptor-activity-modifying proteins or RAMPs, are expressed.
97 suggesting that CLR may associate with other RAMPs in these tissues to form a receptor for additional
98 lem shows that FBA is a limiting case of our RAMP method.
99 ative aggregated microstructural parameters (RAMPs).
100 cts a robust analysis of metabolic pathways (RAMP).
101                                         Penn-RAMP is more sensitive than LAMP or RPA alone.
102                                         Penn-RAMP was implemented in a single pot comprised of two co
103                                         Penn-RAMP's first stage is comprised of recombinase polymeras
104 itive, two-stage, isothermal molecular (Penn-RAMP) point-of-care tests to enable test and treat strat
105  Regionalized Air Quality Model Performance (RAMP) approach to integrate chemical transport model (CT
106  call Ratio Analysis of Multiple Precursors (RAMP).
107                                The predicted RAMP protein exhibits strong homology to the product of
108  the receptor (CRLR), the chaperone protein (RAMP), and RCP that couples the receptor to the cellular
109 equires receptor activity modifying protein (RAMP) 1 to give a calcitonin gene-related peptide (CGRP)
110  called receptor activity-modifying protein (RAMP) 1.
111  of the receptor activity modifying protein (RAMP) family, which results in the formation of two diff
112 , human receptor activity-modifying protein (RAMP)-1, RAMP1 (AMY(1)R), human RAMP2 (AMY(2)R), or huma
113 ncoding receptor activity-modifying protein (RAMP)-like triterpene glycoside receptor (RL-TGR), a nov
114 rafish, receptor activity modifying protein (RAMP)-like triterpene glycoside receptor (RL-TGR), was p
115 ferent receptor activity modifying proteins (RAMP) to become a functional calcitonin gene-related pep
116  reversible association with motor proteins (RAMP), for manipulation of organelle positioning within
117        Receptor activity-modifying proteins (RAMPs 1-3) are single transmembrane accessory proteins c
118        Receptor activity-modifying proteins (RAMPs) 1, 2, and 3 are unusual accessory proteins that d
119        Receptor-activity-modifying proteins (RAMPs) are single transmembrane-spanning proteins which
120        Receptor-activity-modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that
121        Receptor activity-modifying proteins (RAMPs) are widely expressed in human tissues and, in som
122        Receptor activity-modifying proteins (RAMPs) form complexes with G protein-coupled receptors (
123 ), and receptor activity modifying proteins (RAMPs) have become recognized as integral components of
124  three receptor activity-modifying proteins (RAMPs) have been recognized as being important for the t
125        Receptor activity-modifying proteins (RAMPs) interact with G-protein-coupled receptors (GPCRs)
126        Receptor activity-modifying proteins (RAMPs) modulate the activity of many Family B GPCRs.
127        Receptor activity-modifying proteins (RAMPs) offer the potential to do both, through modulatio
128  three receptor activity-modifying proteins (RAMPs) showed that a CRLR/RAMP receptor complex is requi
129 3 with receptor activity-modifying proteins (RAMPs), and RAMP3 has been shown to facilitate ACKR3's r
130 t with receptor activity-modifying proteins (RAMPs), which can modulate different aspects of GPCR bio
131 own as receptor activity-modifying proteins (RAMPs).
132  three receptor activity-modifying proteins (RAMPs).
133 g the repeat-associated mysterious proteins (RAMPs).
134 spital risk-adjusted margin positivity rate (RAMP) that allows identification of performance-based ou
135  further explore the utility of the receptor-RAMP interface as a pharmacological target.
136                   Consequently, the receptor-RAMP interface represents an attractive pharmacological
137  None of the mutations significantly reduced RAMP expression.
138 ferred conformation of peptides that require RAMPs; CGRP, AM, and amylin.
139                   In addition, the resulting RAMP-GPCR interaction map suggests that RAMP1 and RAMP3
140             Most notably, we identify robust RAMP interaction with atypical chemokine receptors (ACKR
141 (R)-1-amino-2-methoxymethylpyrrolidine (SAMP/RAMP)hydrazones.
142 ocedure involving the metalation of the SAMP/RAMP hydrazones of N-Boc-azetidin-3-one, reaction with a
143 (up to 84% ee) by the metalation of the SAMP/RAMP hydrazones of oxetan-3-one, followed by reaction wi
144 ne) except for chromium (up to 4.8x) in some RAMP samples.
145                                    Tethering RAMPs to CTR enhanced binding of rAmy, CGRP, and the AMY
146  truncated receptor variant, suggesting that RAMP regulation involves contacts with the transmembrane
147                           We discovered that RAMPs and GPCRs tend to have orthologs in the same speci
148  selectivity and support the hypothesis that RAMPs allosterically modulate CTR peptide affinity.
149                     These data indicate that RAMPs are necessary and sufficient to determine ligand s
150        Taken together, our results show that RAMPs regulate the CXCL12 signaling axis by directly int
151 ency for CGRP signaling and binding, and the RAMP 1-ECD mutant had a 4000-fold decrease in potency.
152 med prokaryotic silencing (psi)RNAs) and the RAMP module (or Cmr) Cas proteins.
153 in represents a nonselective agonist for the RAMP coreceptors.
154                                 However, the RAMP 1/platelet-derived growth factor receptor chimera d
155 a TM domain and the specific sequence of the RAMP 1 TM domain contribute to CGRP affinity and potency
156 pendent on the intramembranous region of the RAMP and TM6 and TM7 of this receptor.
157 ng and molecular dynamics simulations of the RAMP-GPCR-G protein complexes.
158 ectrical reliability, we anticipate that the RAMP system will suggest a previously unexplored approac
159   By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression
160 urrent electroluminescence display using the RAMP system.
161 ozone observations only in contrast with the RAMP and a Constant Air Quality Model Performance (CAMP)
162                                          The RAMPs augment the binding site with distinct contacts to
163                                        These RAMP 1 mutants were examined for their ability to associ
164                                        These RAMP genes are indispensable for CRISPR3* to affect deve
165                   In humans, there are three RAMPs and over 800 expressed GPCRs, making direct experi
166 coexpressed each GPCR with each of the three RAMPs.
167                                        Thus, RAMP association with chemokine receptor family members
168                The glycan effect extended to RAMP-CTR amylin receptor complexes and was also conserve
169  be structurally and functionally related to RAMPs, a family of coreceptors that physically associate
170 e new studies reveal previously unrecognized RAMP-interacting GPCRs, many of which expand beyond Clas
171 t-mediated receptor-actin-myosin polarity (W-RAMP) structure accumulates asymmetrically at the cell p
172                             However, whether RAMP-GPCR interactions are widespread, and the nature of
173                        It is unclear whether RAMPs use a similar mechanism to modulate CTR affinity f
174 y expressed GPCRs that formed complexes with RAMPs.
175 nical and damage fields, in conjunction with RAMPs, provide a comprehensive time-dependent dataset fo
176 hypothesis that GPCRs interact globally with RAMPs in cellular signaling pathways.
177 n assay, we show that MRGPRX4 interacts with RAMPs.
178 ucts of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.

 
Page Top